8-K: Aethlon Medical Faces Nasdaq Delisting Threat

Aethlon Medical, Inc. received a Nasdaq delisting notice due to its common stock trading below the $1.00 minimum bid price requirement, prompting a hearing request and a 1-for-10 reverse stock split.

Summary

• Aethlon Medical, Inc. (AEMD) received a notification from Nasdaq on October 16, 2025, stating non-compliance with the minimum bid price requirement.
• The company's common stock closing bid price was below $1.00 per share for 30 consecutive business days, violating Nasdaq Marketplace Rule 5550(a)(2).
• Aethlon Medical has filed a request for a hearing before the Nasdaq Hearings Panel, which automatically stays any suspension or delisting action.
• The company's common stock will continue to trade on the Nasdaq Capital Market under the symbol AEMD during the stay.
• To regain compliance, the company implemented a 1-for-10 reverse stock split, effective October 16, 2025, with post-split trading commencing on October 20, 2025.
• Management is actively monitoring the common stock's closing bid price and will evaluate additional actions to maintain its Nasdaq listing.

Sentiment

Score: 3

Explanation: The company received a delisting notice from Nasdaq, indicating significant operational or market challenges leading to a sustained low stock price. While a reverse split and hearing request are proactive, the underlying issue remains, creating substantial uncertainty.

Positives

• The company's request for a hearing before the Nasdaq Hearings Panel automatically stays any suspension or delisting action, allowing continued trading on Nasdaq.
• Aethlon Medical has proactively implemented a 1-for-10 reverse stock split, effective October 16, 2025, as a measure to regain compliance with the minimum bid price requirement.

Negatives

• Aethlon Medical received a delisting notification from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.
• The company's common stock traded below $1.00 for 30 consecutive business days, indicating sustained low market valuation.
• The necessity of a reverse stock split often signals underlying challenges and can be perceived negatively by investors, potentially leading to further price volatility.

Risks

• There is a risk that Aethlon Medical may not regain compliance with Nasdaq's continued listing requirements.
• The company faces the potential delisting of its shares from the Nasdaq Capital Market if it fails to comply with applicable rules.
• The outcome of the Nasdaq Hearings Panel's decision is uncertain and could result in delisting despite the company's efforts.
• The effectiveness of the 1-for-10 reverse stock split in maintaining the bid price above $1.00 for a sustained period is not guaranteed.

Future Outlook

Aethlon Medical is monitoring the closing bid price of its common stock and will evaluate additional actions as appropriate to maintain its listing on the Nasdaq Capital Market. The company acknowledges risks related to its ability to regain compliance and the potential for delisting.

Management Comments

• Management is monitoring the closing bid price of the common stock and will evaluate additional actions as appropriate to maintain the company's listing on the Nasdaq Capital Market.

Industry Context

The situation faced by Aethlon Medical, involving a delisting notice due to a low bid price and the subsequent implementation of a reverse stock split, is a common occurrence for smaller-cap companies struggling with market valuation. Such actions are standard procedures to maintain exchange listing, which is crucial for liquidity and investor confidence.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders face uncertainty regarding the company's continued listing on Nasdaq, which could impact liquidity and investor confidence.
• The 1-for-10 reverse stock split, while intended to boost share price, reduces the number of outstanding shares and can be perceived negatively by some investors.

Next Steps

• The Nasdaq Hearings Panel will make a decision regarding the company's continued listing.
• Aethlon Medical will continue to monitor the closing bid price of its common stock.
• Management will evaluate additional actions as appropriate to maintain the company's listing on the Nasdaq Capital Market.

Key Dates

Recommendation

The company is actively addressing the Nasdaq delisting threat through a reverse stock split and a hearing request, which provides a temporary stay. However, the underlying issues causing the low stock price persist, and the outcome of the Nasdaq hearing and the effectiveness of the reverse split in maintaining compliance are uncertain. Investors should hold and monitor developments closely.

Keywords

Aethlon Medical, AEMD, Nasdaq, delisting, reverse stock split, minimum bid price, compliance, stock market, corporate governance